New hope for Tough-to-Treat breast cancer: experimental combo targets tumors
NCT ID NCT07153965
Summary
This study is testing whether combining two drugs—sacituzumab tirumotecan and tagitanlimab—can help control advanced triple-negative breast cancer that has a specific marker (PD-L1 positive) and has worsened after initial treatment. It will involve about 47 adults whose cancer cannot be surgically removed and has spread. The main goal is to see how many patients' tumors shrink and to monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 30000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.